Company Overview: VRTX

Upcoming Projects (VRTX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (VRTX)

Advancing Cystic Fibrosis Therapy: A Comprehensive Evaluation of Vertex Pharmaceuticals' Kaftrio (VX-121 + TEZACAFTOR + VX-561) in the Vanza Triple Program
Ticker: VRTX
Executed On: Feb 12, 2024 at 10:15 AM EST
A Second View: Revolutionizing Sickle Cell Disease and Thalassemia Treatment: A Deep Dive into the EDIT-301 ASH Clinical Data Abstract and the approval of CASGEVY & Lyfgenia
Tickers: EDIT, BLUE, CRSP, VRTX, BBIO
Executed On: Dec 20, 2023 at 04:00 PM EST
Revolutionizing Sickle Cell Disease and Thalassemia Treatment: A Deep Dive into the EDIT-301 ASH Clinical Data Abstract and the approval of CASGEVY & Lyfgenia
Tickers: EDIT, BLUE, CRSP, VRTX, BBIO
Executed On: Dec 20, 2023 at 01:30 PM EST
Evaluating Vertex Pharmaceuticals Incorporated's VX-880 for the Treatment of Type 1 Diabetes (T1D) with Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Ticker: VRTX
Executed On: Nov 08, 2023 at 11:30 AM EST
Discussing the potential of Vertex' VX-548 with a focus on the NEJM article "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain"
Ticker: VRTX
Executed On: Sep 25, 2023 at 12:15 PM EDT
An updated look at Vertex & CRISPR's exa-cel in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Sep 01, 2023 at 11:30 AM EDT
Discussing the data from Cohort 1 from the 4D-710 phase 1/2 AEROW trial from 4D Molecular Therapeutics in treating cystic fibrosis
Tickers: FDMT, VRTX
Executed On: Jun 15, 2023 at 04:00 PM EDT
A Second View: Discussing the potential Vertex & CRISPR's exa-cel in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Apr 26, 2023 at 10:30 AM EDT
Reviewing EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: EDIT, VRTX, BLUE, CRSP
Executed On: Mar 03, 2023 at 10:00 AM EST
Discussing the potential Vertex & CRISPR's exa-cel in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Jan 26, 2023 at 12:00 PM EST
A discussion of Fazirsiran and its potential in A1AT liver disease ahead of the phase 2 placebo controlled SEQUOIA trial
Tickers: ARWR, VRTX, INBX
Executed On: Nov 18, 2022 at 12:00 PM EST
Checking in on the cystic fibrosis landscape with a prescriber of Vertex' Kalydeco, Orkambi, and Symdeko
Ticker: VRTX
Executed On: Oct 27, 2022 at 10:00 AM EDT

Expired Projects (VRTX)

An in-depth look at the Gene Therapy Landscape
Tickers: VRTX, BLUE, ONCE, CRSP, EDIT, NTLA
Execute By: Dec 31, 2021
Analyzing Recent Developments in Induced Pluripotent Stem Cell Therapy
Tickers: PSTI, VRTX, Healios KK, 4593:Tokyo
Execute By: Nov 30, 2021

Upcoming & Overdue Catalysts (VRTX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (VRTX)

Vertex (VRTX) Announces New Drug Submission for TRIKAFTA Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada
Ticker: VRTX
Occurred on: Dec 28, 2020
Based on Phase 3 trial results, Vertex Pharmaceuticals expects to submit an NDA for ORKAMBI as a treatment for cystic fibrosis in patients aged 2-5 with two copies of the F508del mutation in their CFTR gene, in Q1 2018
Ticker: VRTX
Occurred on: Apr 26, 2018
PDUFA date for Vertex Pharmaceutical's Tezacaftor, in combination with ivacaftor as a treatment for cystic fibrosis in paitents 12 years of age and older who have certain genetic markers, is set for February 28, 2018
Ticker: VRTX
Occurred on: Feb 12, 2018
Vertex's Tezacaftor (VX-661) / ivacaftor in treating Cystic fibrosis - Two Copies of the F508del Mutation PDUFA date under priority review February 28, 2018
Ticker: VRTX
Occurred on: Feb 12, 2018
Vertex plans to submit a New Drug Application (NDA) to the FDA for VX-661 in combination with ivacaftor in the second half of 2017
Ticker: VRTX
Occurred on: Aug 24, 2017
Vertex (VRTX) Expects Top-Line Phase 2 Data Evaluating VX-440/Tezacaftor/Kalydeco in ~40 CF Patients With F508del Mutation and One Minimal Function Mutation and ~25 CF patients With Two Copies of the F508del Mutation in H2 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
Phase I safety data on VX-152 / VX-440 expected in second half of 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
VX-152, VX-440 "triplet" potential Phase II efficacy data in hetero CF expected in early 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
Vertex (VRTX) Expects Top-Line Phase 2 Data Evaluating Triple Combination Dosing With VX-152 in ~35 CF Patients With One F508del Mutation and One Minimal Function Mutation and ~25 CF Patients with Two Copies of F508del in H2 2017
Ticker: VRTX
Occurred on: Jul 18, 2017
Phase 3 data of VX-661 in patients with cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation, due 1H 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Phase 3 data of VX-661 in patients with two Copies of the F508del mutation are expected by early 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Data from VX-661 in combination with ivacaftor in approximately 500 people with CF who have two copies of the F508del mutatioion are expected in the first half of 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Data from VX-661 in combination with ivacaftor for One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function are expected in the first half of 2017
Ticker: VRTX
Occurred on: Mar 28, 2017
Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
Tickers: VRTX, CNCE
Occurred on: Mar 06, 2017
Enrollment in VX-661 in combination with ivacaftor in people with gating mutations is expected to complete in late 2016 or early 2017
Ticker: VRTX
Occurred on: Jan 08, 2017
Vertex (VRTX) Announces Phase 3 Results Evaluating ORKAMBI in Children 6-11 with Cystic Fibrosis with Two Copies of F508del Mutation
Ticker: VRTX
Occurred on: Nov 07, 2016
Vertex (VRTX) Initiates Phase 2 Study Evaluating Triple Combination Dosing With VX-152 in ~35 CF Patients With One F508del Mutation and One Minimal Function Mutation and ~25 CF Patients with Two Copies of F508del.
Ticker: VRTX
Occurred on: Oct 25, 2016
Vertex (VRTX) Initiates Phase 2 Study Evaluating VX-440/Tezacaftor/Kalydeco in ~40 CF Patients With F508del Mutation and One Minimal Function Mutation and ~25 CF patients With Two Copies of the F508del Mutation
Ticker: VRTX
Occurred on: Oct 25, 2016
The FDA set a target review date of September 30, 2016 for a decision on Orkambi sNDA in Homozygous patients aged 6-11
Ticker: VRTX
Occurred on: Sep 28, 2016
VX-661 and ivacaftor did not result in a pre-specified improvement in lung function in people with mutations that result in minimal CFTR function; Vertex plans to close this study based on the recommendation of the DSMB
Ticker: VRTX
Occurred on: Aug 15, 2016
Vertex has terminated clinical development of lead pipeline candidate VX-661, in combination with Kalydeco (ivacaftor), for the treatment of cystic fibrosis (CF) patients
Ticker: VRTX
Occurred on: Aug 15, 2016
PDUFA priority review February 6, 2016 for sNDA of ALYDECO (ivacaftor) for Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations
Ticker: VRTX
Occurred on: Feb 05, 2016
FDA rejects Vertex's application for expanded use of KALYDECO
Ticker: VRTX
Occurred on: Feb 05, 2016

Strategic Initiatives (VRTX)

Vertex (VRTX) and Merck KgaA (MKGAY) Announce Collaboration and License Agreement Covering Four Oncology R&D Programs
Tickers: MRK, VRTX, MKGAY
Announcement Date: Jan 11, 2017
Vertex Pharmaceuticals (VRTX) Expands Agreement with Cystic Fibrosis Foundation Therapeutics (CFFT)
Ticker: VRTX
Announcement Date: Oct 14, 2016
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics for Cystic Fibrosis
Tickers: VRTX, Moderna
Announcement Date: Jul 06, 2016

VRTX Overview